Qilu Pharma Unveils First-in-Human Phase I Data of CLDN6-Targeted ADC QLS5132 for Platinum-Resistant Ovarian Cancer at AACR 2026

At this year's AACR conference, Qilu Pharmaceutical Co., Ltd. presented QLS5132 for the treatment of patients with platinum-resistant ovarian cancerⅠ First Data Results of Phase Clinical Trials。

Source: AACR Official Website

QLS5132 is Qilu PharmaceuticalIndependently DevelopedAADC Targeting CLDN6, combining the powerful cytotoxic effects of traditional small-molecule drugs with the precise targeting of antibody drugs. As of January 21, 2026, the study enrolled a total of 28 patients with advanced platinum-resistant ovarian cancer, including 26 cases of ovarian cancer and 2 cases of fallopian tube cancer.

The results showed that, in terms of efficacy, among the 18 evaluable patients across all dose groups,Objective Response Rate（ORR）AndDisease Control Rate（DCR）50.0% and 94.4%, respectively, among which 9 subjects achieved partial remission（PR）。In the 17 evaluable patients in the ≥3.2 mg/kg dose group, the ORR and DCR were 52.9% and 100%, respectively.

In terms of safety, 1 case occurred at the dose level of 6.4 mg/kg.DLT. No interstitial lung disease, ocular toxicity, or febrile neutropenia occurred. No TRAE led to treatment discontinuation or death.

In summary, QLS5132 at the potential recommended dose（<6.4 mg/kg）It was well tolerated and demonstrated significant anti-tumor activity in patients.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Collaboration: WeChat insightxb